Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RLMDBullishAnalyst Ratingnews

High materiality8/10

HC Wainwright Initiates RLMD Coverage With Buy on NMIBC NDV-01

Jun 18, 2026, 1:56 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A Buy initiation with a $12 target, coupled with compelling Phase 2 data and a 2047 patent horizon, can attract buyers and lift RLMD toward the target. Risk remains clinical and technical execution can shift sentiment.

AI summary

What happened, with direct paths to the underlying reporting

HC Wainwright initiated coverage on RLMD with a Buy rating and a $12 target, highlighting NDV-01 for NMIBC. New Phase 2 interim data show high complete response rates, especially in BCG-unresponsive patients, and a provisional patent could extend protection to 2047. The stock has surged versus peers, reflecting a shift toward bladder-sparing regimens amid BCG shortages.

HC Wainwright initiates RLMD coverage with Buy and $12 target; NDV-01 highlighted for NMIBC.
NDV-01 Phase 2 interim data show 12-month CR 76%; 80% in BCG-unresponsive patients.
Provisional patent filed April 2026 could extend protection to 2047.
RLMD up 800% YoY vs XBI; market sees multi-agent bladder-sparing potential.
Stock around $6.53; data leverage amid BCG shortages and NMIBC demand.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

HC Wainwright Initiates RLMD Coverage With Buy on NMIBC NDV-01

Relmada discontinues late-stage trials for depression drug, explores sale

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why